For women with irregular ovulation who are trying to conceive after 35, oral ovulation-induction medications are often among the first treatments a healthcare provider discusses. Two of the most commonly prescribed options, clomiphene citrate (Clomid) and letrozole, work differently and may be recommended in different situations.
Understanding the basic distinctions between them can make these conversations feel less overwhelming, even though the decision about which medication, if any, is appropriate should always be made with a fertility specialist.
These medications are often the starting point for women whose fertility evaluation shows irregular or absent ovulation as a contributing factor, whether due to polycystic ovary syndrome, perimenopausal cycle changes, or another cause. Because they are oral, relatively low-cost, and have decades of clinical use behind them, they’re frequently tried before moving to more involved treatments like injectable medications or IVF.
What Research Shows About These Medications
Research summarized by the National Institutes of Health (NIH/PubMed) indicates that letrozole, originally developed as a breast cancer treatment, has become a common first-line option for ovulation induction, particularly for women with polycystic ovary syndrome, with some studies showing comparable or higher live birth rates than clomiphene in certain populations. Clomiphene, used for decades, remains a well-studied and widely accessible option as well.
Professional guidelines from reproductive medicine societies have shifted over the past decade to reflect this evidence, with many specialists now considering letrozole a reasonable first option for women with PCOS-related ovulation issues specifically. That said, individual response to either medication can vary, and some women achieve better results with one over the other for reasons that aren’t always fully understood.
How the Two Medications Differ
Clomiphene works by blocking estrogen receptors in the brain, which signals the body to produce more follicle-stimulating hormone. Letrozole works by temporarily lowering estrogen production, which similarly prompts increased FSH release, but through a different pathway. This distinction can matter for women with certain hormonal profiles, which is one reason luteal phase and hormone testing often factors into treatment planning.
These mechanistic differences also help explain why one medication might work better than the other for a specific individual, even though both ultimately aim to trigger ovulation. A provider familiar with your full hormonal profile is best positioned to recommend a starting point, and to adjust course if the first medication tried doesn’t produce the expected response.
Side Effect Considerations
Both medications can cause side effects such as hot flashes, mood changes, or bloating, though the specific pattern and intensity vary by individual. Some research suggests letrozole may be associated with a thinner effect on the uterine lining compared to clomiphene in some women, though findings are not entirely consistent across studies.
Why Age Can Influence the Approach
For women over 35, providers may be more inclined to move to additional testing or more advanced treatment options sooner if oral medications don’t result in pregnancy within a few cycles, given the more time-sensitive nature of fertility at this age. This is a highly individualized decision that depends on ovarian reserve, cycle history, and overall fertility evaluation findings.
Some providers use a structured approach, monitoring response through bloodwork and ultrasound during a medicated cycle to confirm ovulation is actually occurring and to check whether the uterine lining is developing appropriately. This monitoring can also help identify early on whether a particular medication isn’t producing the intended response, allowing for a timely switch rather than repeating an ineffective cycle multiple times.
What to Expect During a Medicated Cycle
A typical ovulation induction cycle starts with the medication taken for five days early in the cycle, followed by monitoring appointments to track follicle development. Depending on the findings, your provider may recommend timed intercourse, intrauterine insemination, or an adjustment to the dose in a subsequent cycle. Side effects, when they occur, are usually most noticeable during the days the medication is taken and tend to resolve afterward.
It’s common to feel a mix of hope and anxiety during a medicated cycle, particularly when so much of the process involves waiting for monitoring appointments and lab results. Many women find it helpful to have a support person or community — whether a partner, friend, or others going through a similar fertility journey — to help manage the emotional demands of treatment cycles.
Understanding Multiple Pregnancy Risk
Both clomiphene and letrozole carry a modestly increased chance of releasing more than one egg in a cycle, which raises the possibility of a multiple pregnancy compared to unmedicated cycles. Research suggests this risk is generally lower with letrozole than with clomiphene, though it is not eliminated with either medication. This is one reason monitoring during a medicated cycle matters — if scans show multiple mature follicles developing, your provider may discuss adjusting the plan, such as converting to a different approach for that cycle, to manage this risk appropriately.
Discussing your personal feelings about the possibility of a multiple pregnancy before starting treatment can be a useful exercise, since it allows you to enter the process with realistic expectations and can inform decisions your provider makes along the way, such as whether to proceed with intercourse or insemination in a cycle with several mature follicles.
Cost and insurance coverage also vary considerably for ovulation induction medications and the monitoring that accompanies them. Some insurance plans cover diagnostic testing and medication but not monitoring ultrasounds, or vice versa, so confirming coverage details with both your insurer and your clinic’s billing office before starting treatment can help you avoid unexpected expenses partway through a cycle.
A Note on Emotional Readiness
Starting any medicated fertility cycle is as much an emotional decision as a medical one. Giving yourself permission to pause, ask more questions, or seek a second opinion before beginning treatment is entirely reasonable, and a good fertility provider will welcome that thoroughness rather than rush you toward a decision.
Frequently Asked Questions
Is letrozole better than Clomid after 35?
Neither medication is universally “better” — the appropriate choice depends on individual factors such as the underlying cause of irregular ovulation, prior response to treatment, and a provider’s clinical judgment.
How many cycles of ovulation induction are typically tried?
This varies by provider and individual circumstances, but many fertility specialists reassess after three to six cycles, particularly for women over 35.
Can these medications be used alongside other fertility treatments?
Yes, they are sometimes combined with intrauterine insemination or used as part of a broader treatment plan. Your fertility specialist can explain what combination, if any, fits your situation.
Key Takeaways
- Clomiphene and letrozole both stimulate ovulation but work through different hormonal pathways.
- Research suggests letrozole may offer comparable or higher success rates for some patient groups.
- Side effects and individual response vary, so treatment is typically individualized.
- Providers often reassess the plan sooner for women over 35 given time-sensitive fertility considerations.
Medical Disclaimer
This content is for informational purposes only and does not constitute medical advice. Individual health situations vary significantly. Always consult a qualified healthcare provider before making decisions related to your health, fertility, or pregnancy.
About the Author
Emily Carter is a women’s health writer focused on fertility, pregnancy after 35, and sleep changes in midlife. She writes research-informed, non-alarmist content to help women navigate reproductive and hormonal transitions with clarity and confidence.